Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,931.11 +2,220.55 (+3.38%) CMC Crypto 200
1,361.88 +31.28 (+2.33%)
Organigram Holdings Inc. (OGI.TO)
| Previous close | 2.2400 |
| Open | 2.2500 |
| Bid | 2.2400 x N/A |
| Ask | 2.2800 x N/A |
| Day's range | 2.2300 - 2.2850 |
| 52-week range | 1.3500 - 3.9500 |
| Volume | |
| Avg. volume | 240,422 |
| Market cap | 232.263M |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Organigram to Bolster Auto-Flower and Rare Cannabinoid Portfolio with Partial Third Tranche Investment of US $1M into Phylos
TORONTO, July 24, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has completed an early partial funding of its final third tranche investment into Phylos Bioscience Inc. ("Phylos"), a U.S. cannabis genetics company and provider of production ready seeds, with the remaining portion of the final tranche to be funded upon completion of the newly expanded final milestone.
- Business Wire
Organigram Invests in Sanity Group, a Leading German Cannabis Company
TORONTO, June 25, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its first significant strategic investment aimed at expanding its presence in the European cannabis market. Using proceeds from its Jupiter strategic investment pool, the Company has agreed to invest €14 million (~ C$21 million) initially comprised of €11.5 million via an unsecured convertible note and €2.5 million to purchase
- Business Wire
Organigram Signs Three Year Supply Agreement with Avida Medical in UK
TORONTO, May 28, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its second international medical cannabis customer in the UK, Avida Medical, a full-service medical cannabis and specials medicines manufacturing business.
